Ivermectin as a possible ally in the treatment of COVID-19: perspectives on its antiviral action
DOI:
https://doi.org/10.33448/rsd-v9i8.6234Keywords:
Treatment; COVID-19; SARS-CoV-2; Ivermectin.Abstract
The outbreak of infections caused by the SARS-CoV-2 has affected the health of a large number of people worldwide, without a consolidated therapy with proven benefit for reducing morbidity and mortality in the early stages of COVID-19. In view of this, the already known viricidal action of ivermectin has fostered studies that established the effectiveness of this drug as a therapeutic option in the clinical treatment of the disease. Thus, this article seeks to summarize the main and most recent evidence of the antiviral effect of ivermectin in the treatment of SARS-CoV-2 infection. The guideline PRISMA 2009 and the PICOS strategy were used as the basis for the study. The articles were searched using the “advanced” tool in the PubMed database, where the association between the pre-established MeSH descriptors and the Boolean operators AND and OR was used, and 10 articles were found. Among these, after applying the eligibility criteria, 4 papers were included in this study. The results revealed that interventions using ivermectin in vitro for 48 hours are statistically significant, decreasing viral replication by up to 5000 times. However, the effectiveness of the drug in vivo against SARS-CoV-2 still needs investigation, and clinical studies are necessary in order to elucidate this problem.
References
Bray, M., Rayner, C., Noël, F., Jans, D., & Wagstaff, K. (2020). Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses. Antiviral research, 178, 104805.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral research, 178, 104787.
Chaccour, C., Hammann, F., Ramón-García, S., & Rabinovich, N. R. (2020). Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. The American journal of tropical medicine and hygiene, 102(6), 1156–1157.
Choudhary, R., Sharma, A. K., & Choudhary, R. (2020). Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. New microbes and new infections, 35, 100684.
Santos, Cristina Mamédio da Costa, Pimenta, Cibele Andrucioli de Mattos, & Nobre, Moacyr Roberto Cuce. (2007). A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Revista Latino-Americana de Enfermagem, 15(3), 508-511.
Galvão, Taís Freire, Pansani, Thais de Souza Andrade, & Harrad, David. (2015). Principais itens para relatar Revisões sistemáticas e Meta-análises: A recomendação PRISMA. Epidemiologia e Serviços de Saúde, 24(2), 335-342.
Gupta, P., Goyal, K., Kanta, P., Ghosh, A., & Singh, M. P. (2019). Novel 2019-coronavirus on new year's Eve. Indian journal of medical microbiology, 37(4), 459–477.
Hamed M. A. (2020). An overview on COVID-19: reality and expectation. Bulletin of the National Research Centre, 44(1), 86.
Heidary F, Gharebaghi R. (2020). Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo), 2020;1-10.
Jean SS, Hsueh PR. (2020). Old and re-purposed drugs for the treatment of COVID-19. Expert Rev Anti Infect Ther, 2020;1-5.
Kelleni MT. (2020). Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacol Res, 157:104874.
Kumar M, Taki K, Gahlot R, Sharma A, Dhangar K. (2020). A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment. Sci Total Environ, 734:139278.
Patrì A, Fabbrocini G. (2020). Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? J Am Acad Dermatol, 82(6):e221.
Rahman MT, Idid SZ. Can Zn Be a Critical Element in COVID-19 Treatment? (2020). Biol Trace Elem Res, 2020;1-9.
Schmith VD, Zhou JJ, Lohmer LRL. (2020). The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. Clin Pharmacol Ther, 10.1002/cpt.1889.
Şimşek Yavuz S, Ünal S. (2020). Antiviral treatment of COVID-19. Turk J Med Sci, 50(SI-1):611-619.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 José Gustavo de Aguiar Lopes, Douglas Figueiredo Santos, Hianny Ribeiro Cabral, Paulo Roberto da Silva Júnior, Arícia Aragão Silva, Yohana da Silva Moura, Carlos Eduardo Nascimento Domingues da Silva, Guilherme Veras Mascena, Adriana Amorim de Farias Leal
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
